St.-Johannes-Hospital Dortmund

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Hematological Malignancy, Higher-risk Myelodysplastic Syndromes, Hematology +6

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

Alan F. List, Gordon W. Dewald, John M. Bennett et al. · New England Journal of Medicine · 2006 · 1.3K citations

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

José Baselga, Ian Bradbury, Holger Eidtmann et al. · The Lancet · 2012 · 1.3K citations · Full text

Breast Oncology, Oncology, Pathology +5

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

Detlef Haase, Ulrich Germing, Julie Schanz et al. · Blood · 2007 · 783 citations · Full text

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

George Dangas, Jan G.P. Tijssen, Jochen Wöhrle et al. · New England Journal of Medicine · 2019 · 526 citations · Full text